ReviewViruses2025
A Comprehensive Review of the Neglected and Emerging Oropouche Virus.
Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Oropouche virus infection: clinical spectrum, geographic expansion, and emerging maternal-fetal implications.Infection · 2026Review
- Low Generation Culex quinquefasciatus from Texas and Culex pipiens from New Jersey Are Incompetent Vectors for Oropouche Virus.The American journal of tropical medicine and hygiene · 2026Article
- Pediatric Arboviral Infections in Europe: Epidemiology, Clinical Features, Diagnosis and Prevention.Viruses · 2026Review
- Comparative analysis of host responses to Oropouche viruses in placental cell infection models.PLoS neglected tropical diseases · 2026Article
- Review
- Five Hot Topics in Tropical Medicine: 2025.Infectious disease reports · 2026Review
- Are mosquito species present in Spain competent for Oropouche virus?Parasites & vectors · 2026Article
- Oropouche virus: transmission, epidemiology, genetic diversity, and public health implications.EClinicalMedicine · 2026Review
- Oropouche virus outbreaks in northeast Brazil between 2024-25 are characterized by sustained transmission and spread to newly affected areas.PLoS neglected tropical diseases · 2026Article
- The global outbreak of Oropouche virus: surveillance of global trends.Tropical diseases, travel medicine and vaccines · 2026Review
- Oropouche Virus (OROV) Vaccine Development for Vulnerable Populations: Epidemiological Context, Challenges and Future Directions.Vaccines · 2026Review
- Article
- Clinical and Epidemiological Characteristics of an Oropouche Virus Outbreak in Loreto, Peru (October 2024-March 2025).Pathogens (Basel, Switzerland) · 2026Observational
- Auto-Abs against type I IFNs: Strong, common, and global determinants of severe arboviral diseases.Journal of human immunity · 2026Review
- Review
- Anthropophagic Florida mosquito species are poor vectors of prototype and emerging strains of oropouche virus.PLoS neglected tropical diseases · 2025Article
- Oropouche fever: Clinical characteristics and viral-bacterial coinfections in a region of the Peruvian Amazon: A cross-sectional study.IJID regions · 2025Article
- Structure-Based Identification of Natural Inhibitors Targeting the Gc Glycoprotein of Oropouche Virus: An In Silico Approach.International journal of molecular sciences · 2025Article
- Oropouche Virus: An Emerging Arboviral Threat and Its Implications for Europe.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oropouche virus (OROV) is a neglected and emerging arbovirus that infects humans and animals in South and Central America. OROV is primarily transmitted to humans through the bites of infected midges and possibly some mosquitoes. It is the causative agent of Oropouche fever, which has high morbidity but low mortality rates in humans. The disease manifests in humans as high fever, headache, myalgia, arthralgia, photophobia, and, in some cases, meningitis and encephalitis. Additionally, a recent report suggests that OROV may cause fetal death, miscarriage, and microcephaly in newborns when women are infected during pregnancy, similar to the issues caused by the Zika virus (ZIKV), another mosquito-borne disease in the same regions. OROV was first reported in the mid-20th century in the Amazon basin. Since then, over 30 epidemics and more than 500,000 infection cases have been reported. The actual case numbers may be much higher due to frequent misdiagnosis, as OROV infection presents similar clinical symptoms to other co-circulating viruses, such as dengue virus (DENV), chikungunya virus (CHIKV), ZIKV, and West Nile virus (WNV). Due to climate change, increased travel, and urbanization, OROV infections have occurred at an increasing pace and have spread to new regions, with the potential to reach North America. According to the World Health Organization (WHO), over 10,000 cases were reported in 2024, including in areas where it was not previously detected. There is an urgent need to develop vaccines, antivirals, and specific diagnostic tools for OROV diseases. However, little is known about this surging virus, and no specific treatments or vaccines are available. In this article, we review the most recent progress in understanding virology, transmission, pathogenesis, diagnosis, host-vector dynamics, and antiviral vaccine development for OROV, and provide implications for future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.